Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s disease candidate, ...

As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW ...

Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients ...

Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

After an FDA rejection of its spinocerebellar ataxia (SCA) therapy, Biohaven was forced to rethink its strategy—cutting R&D spend by 60% and channeling the spirit of a scrappy startup again as it ...

After the FDA's surprise refusal to take up a review of Moderna's next-gen flu vaccine, the public disagreement between U.S.

Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. | Sanofi has backed the $75 million series B of a rhinovirus-focused ...

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...